DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
30 hedge funds and large institutions have $14.4M invested in DMK Pharmaceuticals Corporation Common Stock in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 7 closing their positions.
293% more call options, than puts
Call options by funds: $692K | Put options by funds: $176K
62% more capital invested
Capital invested by funds: $8.88M → $14.4M (+$5.53M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
14% less funds holding
Funds holding: 35 → 30 (-5)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$811K |
| 2 |
BlackRock
New York
|
+$717K |
| 3 |
AI
Axiom Investors
Greenwich,
Connecticut
|
+$350K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$317K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$606K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$52K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$51.5K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
-$48.2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$38.9K |
DMK Hedge Fund Activity: Q1 2017 in Review
30 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2017, worth a combined $14.4M — up 62% from $8.88M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMK and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $811K. The largest seller was Sio Capital Management, cutting an estimated $606K.
- 30 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2017, down from 35 in Q4 2016.
- Funds reported $14.4M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2017, up 62% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2017 and 7 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2017 was Pura Vida Investments, an estimated $811K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2017 was Sio Capital Management, an estimated $606K sold.
Based on aggregated 13F filings for Q1 2017.